Current Report Filing (8-k)
October 31 2018 - 5:23PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR
15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported)
|
October 29, 2018
|
NANOVIRICIDES, INC.
|
(Exact Name of Registrant as Specified in Its Charter)
|
Nevada
|
001-36081
|
76-0674577
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
|
|
1 Controls Drive,
Shelton, Connecticut
|
06484
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
(203) 937-6137
|
(Registrant's Telephone Number, Including Area Code)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 5.02.
|
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
|
Effective
October 29, 2018, the Board of Directors of NanoViricides, Inc. (the “Company”) elected James Sapirstein as a new
member of the Board. Mr. Sapirstein is an Independent Member of the Board of Directors and will serve as a member of the
Company’s Audit, Compensation and Nominating Committees.
James
Sapirstein
,
R.Ph., M.B.A.
57, has served over thirty years in the pharmaceutical industry. He has been
part of almost two dozen product launches and specifically either led or been a key member of several HIV product launches into
a new class of therapeutics at that time. Most recently from March 18, 2014 until October 3, 2018, he served as the Chief
Executive Officer of ContraVir Pharmaceuticals, Inc., which is a company specializing in the Hepatitis B space. After beginning
his career in 1984 with Eli Lilly, he accepted a position at Hoffmann-LaRoche in 1987, where he served for almost a decade as part
of its commercial teams in the US and abroad. He held a number of positions at Hoffmann-LaRoche, before moving to Bristol Myers
Squibb in 1996 the Director of International Marketing in the Infectious Disease group. While at BMS, he worked on several important
HIV/AIDS projects including Secure the Future. Mr. Sapirstein started his career in smaller biotech companies when he later
joined Gilead Sciences, Inc. (GILD) in order to lead the Global Marketing team in its launch of Viread (tenofovir) In 2002, he
accepted the position of Executive Vice President Metabolic and Endocrinology for Serono Laboratories before becoming the founding
CEO of Tobira Therapeutics in 2006. In 2012, after several years in the infectious diseases space, Mr. Sapirstein became
the CEO of Alliqua Therapeutics at Alliqua, Inc., prior to joining Contravir. Mr. Sapirstein holds board positions on Enochian
Biosciences (ENOB), RespireRx Pharmaceuticals (RSPI) and Leading Biosciences. He is also the Chairman of BioNJ and a Board Director
for BIO, where he sits on both the Health Section Governing and Emerging Companies Section Governing Boards. Mr. Sapirstein
received his MBA from Fairleigh Dickinson University and B.Pharm. from Rutgers University. We believe Mr. Sapirstein’s
extensive experience as a biotechnology executive and as a board member in biopharma industry and industry associations qualifies
him to serve as a Director of our Company.
Mr. Sapirstein
executed the Company’s standard form of agreement for its directors. A copy of which is attached hereto as Exhibit 10.1 and
incorporated by reference.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
PURSUANT TO THE REQUIREMENTS OF THE
SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO
DULY AUTHORIZED.
|
NANOVIRICIDES, INC.
|
|
|
|
|
|
Date: October 31, 2018
|
By:
|
/s/ Anil Diwan
|
|
|
Name: Anil Diwan
Title: Chairman, President
|
|
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Aug 2024 to Sep 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Sep 2023 to Sep 2024